BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zigakibart readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zigakibart\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05852938-909@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Zigakibart: Phase 3 readout est. (NCT05852938)
DESCRIPTION:Zigakibart\, phase 3\, Chronic Kidney Disease.\nStudy: A Study 
 of Zigakibart in Adults With IgA Nephropathy\nEstimated primary completion
 : 10 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zig
 akibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05852938
URL:https://assetmemo.bio/drug/zigakibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04573478-909@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20280414
DTEND;VALUE=DATE:20280415
SUMMARY:Zigakibart: Phase 3 readout est. (NCT04573478)
DESCRIPTION:Zigakibart\, phase 3\, Chronic Kidney Disease.\nStudy: Atrasent
 an in Patients With IgA Nephropathy\nEstimated primary completion: 14 Apri
 l 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/zigakibart#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT045734
 78
URL:https://assetmemo.bio/drug/zigakibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07146906-909@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20300712
DTEND;VALUE=DATE:20300713
SUMMARY:Zigakibart: Phase 2 readout est. (NCT07146906)
DESCRIPTION:Zigakibart\, phase 2\, Chronic Kidney Disease.\nStudy: A Study 
 to Assess the Effects of Zigakibart on IgA Nephropathy.\nEstimated primary
  completion: 12 July 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/zigakibart#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07146906
URL:https://assetmemo.bio/drug/zigakibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06858319-909@assetmemo.bio
DTSTAMP:20261121T004017Z
DTSTART;VALUE=DATE:20310625
DTEND;VALUE=DATE:20310626
SUMMARY:Zigakibart: Phase 3 readout est. (NCT06858319)
DESCRIPTION:Zigakibart\, phase 3\, Chronic Kidney Disease.\nStudy: Open-lab
 el Extension Study of Zigakibart in Adults With IgA Nephropathy.\nEstimate
 d primary completion: 25 June 2031. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/zigakibart#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06858319
URL:https://assetmemo.bio/drug/zigakibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
